Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 SEK | -4.43% | -0.98% | -5.03% |
Apr. 30 | OrganoClick AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 23 | OrganoWood AB Announces Three-Year Results from the Field Study EN 12037 for Organowood Nowa | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.03% | 28.65M | D+ | ||
+17.43% | 65.38B | A- | ||
+0.11% | 47.8B | A- | ||
+16.88% | 40.65B | B+ | ||
+23.50% | 26.69B | A- | ||
+12.85% | 19.24B | C+ | ||
+4.74% | 17.75B | B+ | ||
-22.01% | 16B | A- | ||
-8.95% | 15.37B | C+ | ||
+3.47% | 15.23B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- ORGC Stock
- Ratings OrganoClick AB